CEXS-UPF: CompBioMed, a centre of excellence in computational biomedicine, is born

CEXS-UPF: CompBioMed, a centre of excellence in computational biomedicine, is born

News from CEXS-UPF

Predictive models of diseases are gaining importance in medicine thanks to their usefulness when customizing treatments. Hence, computational methods based on human biology have become a key factor for the development of customized medicine.

This scenario has led to the birth of CompBioMed, a centre of excellence in biomedical computing that promotes the uptake and exploitation of high performance computing (HPC) in the field of biomedicine. Basic, clinical and industrial researchers will be able to participate as users in the new project, which, for the moment, will work in three different areas: cardiovascular, molecular and neuromusculoskeletal. University College of London is leading the initiative, which promotes interdisciplinary business opportunities by getting its industrial partners to participate, as well as support and facilitate modelling and simulation activities and provide education to a diverse set of communities.

Among the 14 centres participating in the project is the Computational Biophysics research group at Pompeu Fabra University. The team led by Gianni de Fabritiis, investigator with the Research Programme on Biomedical Informatics (GRIB), a joint programme between UPF and Hospital del Mar Institute of Medical Research (IMIM), will play a substantial role in work package 2 of CompBioMed: Molecularly-based Medicine Exemplar Research, and also in work package 6: Empowering Biomedical Applications.

CompBioMed is part of one of the new centres of excellence funded by the Horizon 2020 programme and has funding of more than 4.9 million euros. In addition to University College of London and Pompeu Fabra University, the universities of Amsterdam, Edinburgh, Oxford, Geneva and Sheffield, as well as the National Supercomputing Centre (Spain); the SURFsara organization (Netherlands); consultant CBK Sci Con (United Kingdom); companies LIFETEC Group (Holland), Bull Sas (France), Janssen Pharmaceutica (Belgium), and laboratories Acellera (Spain) and Evotec Ag (Germany), will be the project partners.

More information: